Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor

Autor: Liddle, John, Atkinson, Francis L., Barker, Michael D., Carter, Paul S., Curtis, Neil R., Davis, Rob P., Douault, Clement, Dickson, Marion C., Elwes, Dorothy, Garton, Neil S., Gray, Matthew, Hayhow, Thomas G., Hobbs, Clare I., Jones, Emma, Leach, Stuart, Leavens, Karen, Lewis, Huw D., McCleary, Scott, Neu, Margarete, Patel, Vipulkumar K., Preston, Alex G.S., Ramirez-Molina, Cesar, Shipley, Tracy J., Skone, Philip A., Smithers, Nick, Somers, Donald O., Walker, Ann L., Watson, Robert J., Weingarten, Gordon G.

Publikováno v: In Bioorganic & Medicinal Chemistry Letters 2011 21(20):6188-6194

The utility of pharmacokinetic-pharmacodynamic modeling in the discovery and optimization of selective S1P1 agonists.

Autor: Taylor, Simon, Gray, James R. J., Willis, Robert, Deeks, Nigel, Haynes, Andrea, Campbell, Colin, Gaskin, Pam, Leavens, Karen, Demont, Emmanuel, Dowell, Simon, Cryan, Jenni, Morse, Mary, Patel, Aarti, Garden, Helen, Witherington, Jason

Publikováno v: Xenobiotica; Jul2012, Vol. 42 Issue 7, p671-686, 16p, 1 Diagram, 4 Charts, 8 Graphs

Depletion of LAG-3 ⁺ T Cells Translated to Pharmacology and Improvement in Psoriasis Disease Activity: A Phase I Randomized Study of mAb GSK2831781.

Autor: Ellis J; GlaxoSmithKline, Stevenage, Hertfordshire, UK., J B Marks D; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Srinivasan N; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Barrett C; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Hopkins TG; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Richards A; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Fuhr R; Parexel International, Berlin, Germany., Albayaty M; Parexel International, London, UK., Coenen M; Study Center Bonn (SZB), Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany., Liefaard L; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Leavens K; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Nevin KL; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Tang S; GlaxoSmithKline, Upper Providence, Pennsylvania, USA., Hughes SA; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Fortunato L; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Edwards K; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Cui Y; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Anselm R; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Delves CJ; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Charles E; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Feeney M; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Webb TM; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Brett SJ; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Schmidt TS; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Stone J; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Savage COS; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Wisniacki N; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Tarzi RM; GlaxoSmithKline, Stevenage, Hertfordshire, UK.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 May; Vol. 109 (5), pp. 1293-1303. Date of Electronic Publication: 2020 Nov 24.